Latest news
FDA Grants Accelerated Approval to Replimune's Tudriqev Plus Nivolumab for Advanced Melanoma - biopharminternational.combiopharminternational.com · Fri, 07 Aug 2026 17:19:39 GMTReplimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:13:55 GMTReplimune Announces Favorable Outcome of FDA’s Advisory Committee Meeting - OncodailyOncodaily · Sun, 02 Aug 2026 09:10:52 GMTFDA Advisory Committee Backs RP1 for Advanced Melanoma - Cure TodayCure Today · Sun, 02 Aug 2026 07:00:00 GMTWhy Replimune Group (REPL) Is Up 15.5% After Key FDA Panel Backing For RP1 Data - And What's Next - Yahoo FinanceYahoo Finance · Sat, 01 Aug 2026 07:00:00 GMTGapping stocks in Friday's session - ChartMillChartMill · Fri, 31 Jul 2026 14:30:00 GMTFDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study - Pharmaceutical ExecutivePharmaceutical Executive · Fri, 31 Jul 2026 07:00:00 GMTReplimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 22:36:54 GMT